KR20230154900A - 갈락토스-결핍 면역글로불린의 이중기능성 분해제 - Google Patents

갈락토스-결핍 면역글로불린의 이중기능성 분해제 Download PDF

Info

Publication number
KR20230154900A
KR20230154900A KR1020237033102A KR20237033102A KR20230154900A KR 20230154900 A KR20230154900 A KR 20230154900A KR 1020237033102 A KR1020237033102 A KR 1020237033102A KR 20237033102 A KR20237033102 A KR 20237033102A KR 20230154900 A KR20230154900 A KR 20230154900A
Authority
KR
South Korea
Prior art keywords
optionally substituted
moiety
group
groups
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237033102A
Other languages
English (en)
Korean (ko)
Inventor
진 엠. 두보치크
데이빗 스피겔
리즈 엠. 콜드웰
Original Assignee
바이오하벤 테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오하벤 테라퓨틱스 리미티드 filed Critical 바이오하벤 테라퓨틱스 리미티드
Publication of KR20230154900A publication Critical patent/KR20230154900A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020237033102A 2021-03-10 2022-03-10 갈락토스-결핍 면역글로불린의 이중기능성 분해제 Pending KR20230154900A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163159383P 2021-03-10 2021-03-10
US63/159,383 2021-03-10
PCT/US2022/019658 WO2022192478A1 (en) 2021-03-10 2022-03-10 Bifunctional degraders of galactose-deficient immunoglobulins

Publications (1)

Publication Number Publication Date
KR20230154900A true KR20230154900A (ko) 2023-11-09

Family

ID=83227063

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237033102A Pending KR20230154900A (ko) 2021-03-10 2022-03-10 갈락토스-결핍 면역글로불린의 이중기능성 분해제

Country Status (11)

Country Link
US (2) US20240309114A1 (cg-RX-API-DMAC10.html)
EP (1) EP4304579A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024509282A (cg-RX-API-DMAC10.html)
KR (1) KR20230154900A (cg-RX-API-DMAC10.html)
CN (1) CN116997337A (cg-RX-API-DMAC10.html)
AU (1) AU2022232620A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023017702A2 (cg-RX-API-DMAC10.html)
CA (1) CA3211335A1 (cg-RX-API-DMAC10.html)
IL (1) IL305665A (cg-RX-API-DMAC10.html)
MX (1) MX2023010424A (cg-RX-API-DMAC10.html)
WO (1) WO2022192478A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12023553152A1 (en) * 2021-05-17 2024-03-11 Biohaven Therapeutics Ltd Compositions including conjugated therapy enhancers
JP2024524614A (ja) 2021-07-14 2024-07-05 ライシア セラピューティクス, インコーポレイテッド Asgpr細胞表面受容体結合化合物及びコンジュゲート
CN121038815A (zh) * 2023-04-29 2025-11-28 拜奥海芬治疗学有限公司 半乳糖缺陷型免疫球蛋白的双功能降解剂
WO2026083257A1 (en) 2024-10-14 2026-04-23 Biohaven Therapeutics Ltd. Antigen-specific degraders of immunoglobulin a and their uses
WO2026120177A1 (en) 2024-12-06 2026-06-11 Ascendis Pharma A/S Novel long-acting degrader conjugates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8440191B2 (en) * 2005-11-18 2013-05-14 Tufts Medical Center Clearance of abnormal IGA1 in IGA1 deposition diseases
DK2991683T3 (da) * 2013-05-02 2019-11-04 Glykos Finland Oy Konjugater af et glykoprotein eller en glykan med en toksisk ladning
CA2946064C (en) * 2014-02-21 2023-09-26 Ecole Polytechnique Federale De Lausanne (Epfl) Glycotargeting therapeutics
RU2696490C2 (ru) * 2014-05-19 2019-08-02 Пфайзер Инк. Замещенные-6,8-диоксабицикло[3.2.1.]октан-2,3-диольные соединения в качестве агентов, нацеленных на ASGPR
CA3134610A1 (en) * 2018-04-09 2019-10-17 Yale University Bifunctional small molecules to target the selective degradation of circulating proteins

Also Published As

Publication number Publication date
US20260146106A1 (en) 2026-05-28
JP2024509282A (ja) 2024-02-29
BR112023017702A2 (pt) 2023-12-12
CA3211335A1 (en) 2022-09-15
MX2023010424A (es) 2023-09-18
EP4304579A4 (en) 2026-06-10
US20240309114A1 (en) 2024-09-19
IL305665A (en) 2023-11-01
WO2022192478A1 (en) 2022-09-15
CN116997337A (zh) 2023-11-03
AU2022232620A1 (en) 2023-09-21
EP4304579A1 (en) 2024-01-17

Similar Documents

Publication Publication Date Title
JP7241811B2 (ja) 四級化チューブリシン化合物の複合体
JP7430643B2 (ja) カンプトテシンペプチドコンジュゲート
JP2024509282A (ja) ガラクトース欠損免疫グロブリンの二官能性分解剤
KR102235870B1 (ko) 접합체 화합물
JP7527978B2 (ja) カンプトテシンコンジュゲート
KR102938500B1 (ko) 항체 약물 접합제용 친수성 링커
US20220241423A1 (en) Camptothecine antibody-drug conjugates and methods of use thereof
KR20230004453A (ko) 캄프토테신 유도체 및 이의 접합체
CN114728073A (zh) 药物从生物活性化合物的内化缀合物的选择性释放
JP7846624B2 (ja) ペプチド含有リンカーとの部位特異的抗体-薬物コンジュゲート
JP2024506300A (ja) 免疫刺激化合物及びコンジュゲート体
CN112955434B (zh) 包含喹啉衍生物的药物偶联物
JP2021513990A (ja) 疎水性アウリスタチンf化合物およびそのコンジュゲート
US20180371060A1 (en) Modified pigment epithelium-derived factor (pedf) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection
EP3946635A2 (en) Locally acting toll-like receptor 7 (tlr7) and/or tlr8 agonist immunotherapy compounds and their uses
US20240197907A1 (en) Dual-Cleavage Ester Linkers for Antibody-Drug Conjugates
JP2004510709A (ja) ペプチドと親油性ベクターとを溶液中で結合するための方法およびその使用
EP4402178A2 (en) Conjugated antibodies for treating diseases
RU2859790C2 (ru) Сложноэфирные линкеры с двойным расщеплением для конъюгатов антитело-лекарственное средство
CN116847844A (zh) 喜树碱抗体-药物缀合物及其使用方法
WO2024098023A2 (en) Interferon alpha polypeptides and conjugates

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000